STAT3 and type 2 diabetes mellitus: Given recent evidence showing that metformin targets STAT3 pathways in triple negative breast cancer cells, and that metformin is widely available and in common clinical use (for type 2 diabetes), metformin has the potential for rapid therapeutic implementation for STAT3-overexpressing cancers[25].